drugset
drugset / Trial / NCT06120712

A Study of GC101 TIL in Advanced Melanoma (BZ)

NCT06120712 ↗

Phase 1/2 Completed 18 enrolled Shanghai Juncell Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

20 participants are expected to be enrolled for the Phase Ib clinical trial，this trail is expected to be finished in 20 months.

Timeline

Start
2023-11-08
Primary completion
2024-11-12
Completion
2025-11-12

Drugs

EvaluationDrugModalityDoseRoute
Subject GC101 TIL Cell therapy — Intravenous

Indications

melanoma